COVID-19 Vaccine Hesitancy and Dental Faculty Staff Members in Egypt

NCT ID: NCT05009043

Last Updated: 2021-08-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-08-15

Study Completion Date

2021-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Healthcare workers (HCWs) play a vital role in determining the success of vaccination programs. Patient acceptance and vaccination rely greatly on the utilization and attitude of HCWs towards the vaccine, their attitude also influences patients' adherence to vaccination schedules and their hesitancy. HCWs themselves can be hesitant about a certain vaccine and thus can transfer their negative attitudes to their patients, increasing vaccine hesitancy among the general population. Frontline HCWs are at an increased risk of exposure to COVID-19 due to their direct contact with their patients, working hours, psychological stress and job burnout, they also face stigma. Dental health professionals in particular are at an increased risk due to their occupational hazards that include continuous exposure to body fluids and aerosols, this increases their risk of contracting COVID-19. Therefore vaccinating healthcare workers will be beneficial, not only for themselves, but also for their households and patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To mitigate the rapid spread of COVID-19 and its massive impact on the economy worldwide, efforts have to be made to protect people against the disease, one of the most effective means was found to be vaccination. The range of technology in the development of COVID-19 vaccine is a striking feature where various approaches are being evaluated including, but not limited to: nucleic acid (DNA and RNA), recombinant protein, live-attenuated virus, inactivated virus and virus-like particles approaches. It is the responsibility of governments to ensure equity in the distribution and access to the novel vaccine. Authorized and currently available vaccines in Egypt include: 1) COVID-19 Vaccine AstraZeneca (AZD1222) which is an adenovirus vaccine manufactured in UK, 2) Sputnik V, a recombinant adenovirus vaccine manufactured in Russia and 3) BBIBP-CorV Sinopharm, which is an inactivated vaccine manufactured in China. The total number of vaccine doses administered in Egypt was reported to be 1,315 doses in March 2021.

However, vaccine availability is not enough to ensure large-scale immunization; success of vaccination programs depend greatly on the population's demand and acceptability of the vaccine. Governments should strive to understand determinants of vaccine acceptability and perception of people towards the vaccine. Although vaccination has largely contributed to decreasing the global burden of diseases and mortality, various factors can affect the acceptance of a new vaccine. "Vaccine hesitancy" has been declared by WHO as one of the ten global health threats worldwide, and has been defined as 'delay in acceptance or refusal of vaccination despite availability of vaccination services.' Causes of vaccine hesitancy include concerns about its safety, efficacy, personal beliefs, religious reasons, concerns about its rapid development as the rapid development of swine flu vaccine was previously associated with increased risk of Guillain-Barre syndrome, low benefits perceived and fear of side effects. Moreover, some people have concerns about the manufacturing process of the vaccine, as a defective polio vaccine lead to development of incident cases of polio and paralysis and death in earlier times.

In Egypt, healthcare workers are the first group to have access to COVID-19 vaccine and hence, act as a primary source of knowledge to the public about the vaccine, therefore it is crucial to estimate their level of perception and acceptability of the vaccine and determine factors affecting their acceptability. This will help inform stakeholders to make decisions regarding COVID-19 vaccination programs. To the best of our knowledge, this is the first study in Egypt targeting dental health professionals in particular, owing to their exclusive high exposure level to COVID-19 among healthcare workers

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Respiratory Infection Covid19 Vaccine Refusal

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Staff members at Faculty of Dentistry, Ain Shams University
* Egyptians.

Exclusion Criteria

* Staff members who refuse to participate in the study.
* Staff members currently living abroad. (As their perception about COVID-19 situation and risk in Egypt will not be accurate)
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Mariam Ayman Amin Sharaf

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mariam Ayman Amin Sharaf

Teaching assistant

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mariam Sharaf, Msc

Role: PRINCIPAL_INVESTIGATOR

Ain Shams University

Amira Badran, PhD

Role: STUDY_DIRECTOR

Ain Shams University

Omar Taqa, Msc

Role: PRINCIPAL_INVESTIGATOR

Ain Shams University

Haneen Zahran, Msc

Role: STUDY_CHAIR

Ain Shams University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ain Shams University

Cairo, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

960

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.